Literature DB >> 16048966

In vitro efficacy of the combination of ciprofloxacin and cefotaxime against Vibrio vulnificus.

Dong-Min Kim1, Yong Lym, Sook Jin Jang, Hulin Han, Young Gi Kim, Choon-Hae Chung, Soon Pyo Hong.   

Abstract

We performed time-kill studies of antimicrobial combinations that included minocycline, cefotaxime, and ciprofloxacin with Vibrio vulnificus ATCC 27562. Cefotaxime-plus-ciprofloxacin combinations acted synergistically against V. vulnificus in vitro, and this combination regimen can be a good choice as the empirical treatment for suspected necrotizing fasciitis due to V. vulnificus.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16048966      PMCID： PMC1196224          DOI： 10.1128/AAC.49.8.3489-3491.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  Antimicrobial susceptibilities of halophilic vibrios.

Authors:  G L French; M L Woo; Y W Hui; K Y Chan
Journal:  J Antimicrob Chemother       Date:  1989-08       Impact factor: 5.790

2.  Antibiotic therapy for Vibrio vulnificus infection.

Authors:  J G Morris; J Tenney
Journal:  JAMA       Date:  1985-02-22       Impact factor: 56.272

3.  In vitro and in vivo activities of newer fluoroquinolones against Vibrio vulnificus.

Authors:  Hung-Jen Tang; Ming-Chung Chang; Wen-Chien Ko; Kun-Yen Huang; Chih-Lung Lee; Yin-Ching Chuang
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

4.  Syndromes of Vibrio vulnificus infections. Clinical and epidemiologic features in Florida cases, 1981-1987.

Authors:  K C Klontz; S Lieb; M Schreiber; H T Janowski; L M Baldy; R A Gunn
Journal:  Ann Intern Med       Date:  1988-08-15       Impact factor: 25.391

5.  Infections caused by halophilic marine Vibrio bacteria.

Authors:  R J Howard; N T Bennett
Journal:  Ann Surg       Date:  1993-05       Impact factor: 12.969

6.  Clinical features and an epidemiological study of Vibrio vulnificus infections.

Authors:  C O Tacket; F Brenner; P A Blake
Journal:  J Infect Dis       Date:  1984-04       Impact factor: 5.226

7.  Routes of quinolone permeation in Escherichia coli.

Authors:  J S Chapman; N H Georgopapadakou
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

8.  Disease caused by a marine Vibrio. Clinical characteristics and epidemiology.

Authors:  P A Blake; M H Merson; R E Weaver; D G Hollis; P C Heublein
Journal:  N Engl J Med       Date:  1979-01-04       Impact factor: 91.245

9.  Effect of temperature and salinity on Vibrio (Beneckea) vulnificus occurrence in a Gulf Coast environment.

Authors:  M T Kelly
Journal:  Appl Environ Microbiol       Date:  1982-10       Impact factor: 4.792

10.  Antibiotic efficacy against Vibrio vulnificus in the mouse: superiority of tetracycline.

Authors:  J H Bowdre; J H Hull; D M Cocchetto
Journal:  J Pharmacol Exp Ther       Date:  1983-06       Impact factor: 4.030
View more
  17 in total

1.  Quantitative PCR and in vivo efficacy of antibiotics in the treatment of Vibrio vulnificus infection in a mouse model.

Authors:  G P Neupane; D-M Kim; N R Yun; S-H Shin; S-C Lim; C-H Choi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-03-21       Impact factor: 3.267

2.  Clinical Usefulness of Real-Time Polymerase Chain Reaction for the Diagnosis of Vibrio vulnificus Infection Using Skin and Soft Tissues.

Authors:  Jun-Young Lee; Seok Won Kim; Dong-Min Kim; Na Ra Yun; Choon-Mee Kim; Sang-Hong Lee
Journal:  Am J Trop Med Hyg       Date:  2017-08       Impact factor: 2.345

3.  Tumor necrosis factor-α and mortality in patients infected with Vibrio vulnificus.

Authors:  Jun-Young Lee; Dong-Min Kim; Na Ra Yun; Ganesh Prasad Neupane; Sook-In Jung; Kyung-Hwa Park; Hee Chang Jang; Chang Seop Lee; Sun Hee Lee
Journal:  Am J Trop Med Hyg       Date:  2011-03       Impact factor: 2.345

4.  In vitro synergism of ciprofloxacin and cefotaxime against nalidixic acid-resistant Salmonella enterica serotypes Paratyphi A and Paratyphi B.

Authors:  Ganesh Prasad Neupane; Dong-Min Kim; Sung Hun Kim; Bok Kwon Lee
Journal:  Antimicrob Agents Chemother       Date:  2010-06-21       Impact factor: 5.191

5.  In Vitro Synergy and In Vivo Activity of Tigecycline-Ciprofloxacin Combination Therapy against Vibrio vulnificus Sepsis.

Authors:  Seong Eun Kim; Hee Kyung Kim; Su-Mi Choi; Yohan Yu; Uh Jin Kim; Kalifa Sanneh Darboe; Seung-Ji Kang; Kyung-Hwa Park; Gaeun Kang; Young Ran Kim; Joon Haeng Rhee; Sook-In Jung; Hee-Chang Jang
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

6.  Vibrio vulnificus DNA load and mortality.

Authors:  Dong-Min Kim; Sook-In Jung; Hee-Chang Jang; Chang Seop Lee; Sun Hee Lee; Na Ra Yun; Ganesh Prasad Neupane; Kyung-Hwa Park
Journal:  J Clin Microbiol       Date:  2010-11-10       Impact factor: 5.948

7.  In vitro time-kill activities of ciprofloxacin alone and in combination with the iron chelator deferasirox against Vibrio vulnificus.

Authors:  G P Neupane; D-M Kim
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-02-02       Impact factor: 3.267

8.  Spontaneous quinolone resistance in the zoonotic serovar of Vibrio vulnificus.

Authors:  Francisco J Roig; A Llorens; B Fouz; C Amaro
Journal:  Appl Environ Microbiol       Date:  2009-02-13       Impact factor: 4.792

9.  Genome sequence of the human-pathogenic bacterium Vibrio vulnificus type strain ATCC 27562.

Authors:  Zhaoyun Li; Huihong Chen; Xianjun Chen; Tieli Zhou; Lei Zhao; Chunling Zhang; Wenyang Jin
Journal:  J Bacteriol       Date:  2012-12       Impact factor: 3.490

10.  Multi-site analysis reveals widespread antibiotic resistance in the marine pathogen Vibrio vulnificus.

Authors:  Craig Baker-Austin; J V McArthur; Angela H Lindell; Meredith S Wright; R Cary Tuckfield; Jan Gooch; Liza Warner; James Oliver; Ramunas Stepanauskas
Journal:  Microb Ecol       Date:  2008-07-19       Impact factor: 4.552
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.